61 results about "Sprague dawley" patented technology

The invention belongs to the technical field of protein polypeptides, relates to a polypeptide with a brain targeted medicine delivery characteristic, and provides a molecular structure of the polypeptide, and application of the polypeptide to brain targeted medicine delivery. A phage monoclonal antibody which has the function of penetrating a blood brain barrier and can be enriched in a brain is obtained through repeated in-vivo Sprague Dawley (SD) outbred stock rat screening by a phage display technology; deoxyribonucleic acid (DNA) sequencing proves that the phase display polypeptides comprise a consensus sequence; meanwhile, an immunohistochemical method and in-vivo recovery rate comparison prove that the obtained polypeptide has the brain targeted medicine delivery characteristic. The polypeptide and derivative peptides thereof can be used for modifying medicine-carrying nanoparticles, liposomes, vesicles or micelles to construct a brain targeted medicine delivery system; and the delivery of medicines in the brain can be improved, the treatment effect on brain diseases is enhanced and systemic toxic and side effects are reduced.

The invention relates to a pulsatile delivery sustained-release tablet for treating diabetes mellitus and a preparation method thereof. The active components of the pulsatile delivery sustained-release tablet liraglutide, exenatide acetate or pramlintide acetate are respectively combined with insulin, and drugs are released according to a preset time. According to the pulsatile delivery sustained-release tablet, a polymer material is adopted as a coating film, the active components are combined with a swelling coating to serve as a tablet core, and medical auxiliaries are adopted. The dissolution percentage of the composition is further investigated, and an SD (sprague-dawley) diabetes rat model is used as a studying object to detect the fasting blood-glucose, 2hplasmaglucose, number of hypoglycemia times, dawn phenomenon indexes of the rat model, and the treatment effects are investigated.

The invention discloses a rhizoma bletillae extract and application thereof. The rhizoma bletillae extract is prepared by the following steps: carrying out backflow extraction on dried rhizoma bletillae powder with a 60-90% ethanol solution, filtering, and collecting filtrate so as to obtain a rhizoma bletillae alcohol extract; adsorbing the rhizoma bletillae extract with polyamide and a D101 macroporous resin in sequence, collecting a 35-45% ethanol eluant, and carrying out vacuum evaporation drying, thereby obtaining the rhizoma bletillae extract. In-vivo SD (Sprague Dawley) rat chronic bronchitis mode experiments show that rhizoma bletillae and an effective part EFB have a treatment function on chronic bronchitis by inhibiting inflammatory factors such as TNF-alpha, IL-1 beta and IL-6,and by increasing oxidation stress levels.

The invention discloses a Sprague-Dawley rat-based suicide relevant behavior animal model construction method, and belongs to the field of animal model construction. The method comprises the step that learned helplessness rats and non-learned helplessness rats are screened out from a learned helplessness model, and accept social defeat stimulation overlaid chronic unpredictable mild stimulation in four weeks. The behavioristics analysis finds that the rat model shows that the rats have typical suicide relevant behaviors after the four-weak stress, and the rats have the typical suicide characteristics such as invasion, impulsion, irritability and desperation. Successful construction of the model provides a novel research carrier for a research mechanism for researching suicide relevant behaviors.

The invention relates to application of tanshinone IIA derivative in the preparation of ischemic stroke drugs and belongs to the field of medicine. The high-molecular tanshinone IIA derivative is synthesized herein; pharmacological experiment studies on animals are carried out; experimental results show that the high-molecular tanshinone IIA derivative can well protect cerebral ischemia-reperfusion injury in MCAO (middle cerebral artery occlusion) animal model of an SD (Sprague Dawley) rat; compared with positive controls, the high-molecular tanshinone IIA derivative can evidently improve neurological behaviors, cerebral infarction area and encephaledema of the rat with focal cerebral ischemia. The high-molecular tanshinone IIA derivative provided by the invention helps provide a new ideafor treating ischemic stroke, and has the potential of being developed into drugs to treat ischemic stroke.

The invention discloses a separating and extracting method and special culture medium for rat omentum majus adipose mesenchymal stem cells. The method comprises the following steps: taking omentum majus fat of a healthy Sprague Dawley (SD) rat under an aseptic condition; cutting into pieces, centrifuging after being mixed with cold phosphate buffer to wipe off partial adipose tissues; digesting and centrifuging by mixed collagenase of I type collagenase and II type collagenase to wipe off upper adipose tissues; centrifuging again; suspending again in the special culture medium containing particular chemical substances and growth factor; moving into a culture flask; putting into an incubator to subculture continuously. The method is used to extract the omentum majus adipose source mesenchymal stem cells from a rat body; meanwhile, during the culturing, the problem that cell senescence and cell differentiation easily occur when stem cells are cultured in vitro can be solved through the special culture medium containing particular chemical substances and growth factor; and the omentum majus adipose source mesenchymal stem cells that can maintain characteristics of stem cells for a long time can be obtained.

The invention discloses a streptococcus mutans infection and cariogenic animal model establishing method, belonging to the technical field of microbiology. Through streptococcus mutans oral infection, a specimen is collected after 80 days, the streptococcus mutans infection is identified by adopting a plate cultivation method, and cariogenicity is observed through dyeing and teeth are evaluated. According to the invention, streptococcus mutans and Carbomer 940 are mixed, and are used for orally infecting an SD (Sprague Dawley) rat, the infection condition is easily controlled, the infection rate is high (more than 90 percent), and the infection is stable. The SD rat is infected by using the method and is fed with high-sugar feeds, and thus remarkable cariogenicity can be caused.

The invention relates to application of chickpea sprout extracts in medicines for preventing deficiency of estrogen. The chickpea sprout extracts are chickpea sprout isoflavone extracts, are used as estrogen receptor regulator, and are used for preparing medicines and health care products which are used for preventing or treating climacteric syndrome and osteoporosis. Tests show that the chickpea sprout isoflavone extracts can directly act onto the uterus of a patient, can remarkably increase estradiol level in blood serum, have regulating and controlling effects to a hypothalamus-hypophysis- neuroendocrine system, remarkably increase thighbone density and relative bone volume of an SD (Sprague Dawley) rat without the ovary, increase the thickness of bone trabecula, reduce separating degree of the bone trabecula, decrease the quantity of osteoclast, can alleviate bone loss of the thighbone of the rat due to the fact that the ovary of the rat is removed, increase bearing capacity of the thighbone, play an important role in regulating internal secretion conditions of middle-aged and elderly women after menopause, improving menopause symptoms such as hot flash, palpitate, skin dryness and the like and reducing possibility of osteoporosis, and lay a foundation in industrial development of functional factors of chickpeas.

The invention discloses an establishment method of a diarrhea-type irritable bowel syndrome compound animal model. The establishment method specifically comprises the steps of repurchasing Sprague-Dawley pregnant rats for predelivery, and recording the delivery date. The method comprises the procedures of 1, colorectum stimulation in the neonatal stage, wherein colorectum stimulation is separatelyconducted in the 8 th day, the 10 th day and the 12 th day after the birth of modeling groups of young rats, a percutaneous transluminal coronary angioplasty balloon is inserted in the colorectum viathe anus, after the balloon completely enters the colorectum, gas is injected into the balloon, so that the pressure in the balloon is 60 mmHg and is kept for 1 minute, stimulation is conducted onceevery day and conducted three times in total, after stimulation, the young rats and mother rats are fed together to the 22 nd day and then weaned, cage allocation is conducted on the 30 th day, then normal feeding is conducted, 60 days after the birth, abdominal wall withdrawal reflex examination is conduced, intestinal-tract high-sensitivity rats are screened out, and the next step of modelling is conducted; 2, gavage with folium sennae juice, wherein folium sennae is put into boiled water which is 5 times the volume of the folium sennae to be soaked for one night, after filtering, a filtrateis taken, and then concentrated until the concentration is 0.45 g/mL, the 0.45 g/mL folium sennae juice is fed for gavage of the screened-out 60-day intestinal tract high-sensitivity rats, 2 mL of the juice is fed to each rat once every day, gavage is continuously conducted for 2 weeks, and then the IBS-D rat model is established.

The invention discloses a construction method of a diabetic cardiomyopathy animal model. An SD (Sprague Dawley) rat under high-sugar and high-fat feeding is subjected to multiple abdominal injection with STZ (streptozocin); after the diabetics diagnosis standard is reached, subcutaneous injection with isoprenaline is performed; after 2 weeks of continued feeding, left ventricular cannulation and three-lead electrocardiogram test of ventricular hemodynamic parameters and electrocardiogram parameters shows that the rat experiences cardiac dysfunction; heart weight index and left ventricular index show that the rat experiences evident ventricular hypertrophy; biochemical analysis on rat blood shows that the rat has evident myocardial damage; HE (hematoxylin-eosin) pathological staining satisfies pathological changes in diabetic cardiomyopathy; Masson collagen staining satisfies myocardial connective tissue proliferation of diabetic cardiomyopathy. The construction method has the advantages of good operational simplicity, short construction time, low mortality in construction phase, high construction success rate and the like, and the pathological process of myocardial damage due to human type 2 diabetes mellitus can be well simulated.

The invention provides an HPLC-MS/MS (High Performance Liquid Chromatography-Mass Spectrum/Mass Spectrum) technique-based method for detecting blood concentration of a NMDA (N Methyl D Aspartate) receptor antagonist JCC-02 and relates to the field of drug analysis. The method comprises the following steps of: sequentially adding methanol, acetonitrile and an internal standard working solution intoplasma of an SD (Sprague Dawley) rat after intragastric administration of the JCC-02, eddying and dissolving supernatant by using a mobile phase to obtain a preprocessed sample, wherein the internalstandard working solution was a gliclazide methanol solution; and carrying out gradient elution by taking acetonitrile-formic acid water mixed solution as a mobile phase and by adopting HPLC-MS/MS technique, carrying out chromatographic separation by using a Venusil ASB C8 chromatographic column, detecting through a second-stage mass spectrometry and carrying out quantitative analysis. The methodhas the advantages of being strong in specificity, high in sensitivity, small in sample sampling amount, simple and rapid in preprocessing and short in analysis period; and proved by methodology, themethod is accurate and reliable and is suitable for drug concentration determination of the JCC-02 in the plasma of the SD rat and pharmacokinetic study.

The invention discloses a construction method of an SD (Sprague Dawley) rat pancreas duct epithelial cell model. The construction method adopts a rat and is characterized by further comprising steps as follows: animal selection and anesthesia, surgical separation of a main pancreatic duct of the rat, chemical digestion of the main pancreatic duct and cell type identification. According to the construction method, the main pancreatic duct is directly separated under the naked eyes according to a pancreatic anatomical structure of the SD rat, the separation recovery rate of epithelial cells of the pancreatic duct is higher, the obtained epithelial cells of the pancreatic duct are less irritated, and stable passage can be realized. The method is simple and convenient, the success rate is high, and the novel cell model with rich and reliable sources is provided for research of diseases of pancreas.

The invention relates to applications of safflower extract with the definite spectrum-effect relationship. An hypoglycemic extract is obtained from safflower carthamus through distilled water reflux extraction and macroporous resin separation and purification, and the medical applications of the hypoglycemic extract are illustrated preliminarily; the sum of the peak areas of hydroxysafflor yellow A and 6-hydroxyl kaempferol-3,6-bis-O-glucose-7-O-glucoside in an HPLC (High Performance Liquid Chromatography) fingerprint of the extract is not less than 50%; through calculation, the peak area ratio of hydroxysafflor yellow A to 6-hydroxyl kaempferol-3,6-bis-O-glucose-7-O-glucoside is 5.0-8.0. The activity screening test proves that the extract obtained by adopting the method provided by the invention has the obvious effect of inhibiting protein-tyrosine-phosphatase 1B (PTP-1B), has the excellent effect of reducing blood glucose on SD (Sprague Dawley) rats suffering from diabetes induced by high-fat diet and streptozotocin (STZ), and can be taken as the raw material or adjuvant to be used for preparing medicines or health products for preventing and treating diabetes.

The invention discloses a construction method of a polycystic ovarian syndrome (PCOS) with type 2 diabetes mellitus rat model and belongs to the technical field of medical animal models. The rat model is constructed through feeding 23-day-age weaned underage female SD (Sprague Dawley) rats with high-fat and high-sugar feed diet, subcutaneously injecting 90Mug/(g.d) sodium prasterone sulfate which is equivalent to 60Mug/(g.d) DHEA (Dehydroepiandrosterone)+0.4mL water for injection every day and continuously injecting for 20d, then fasting for 12 hours and carrying out intraperitoneal injection of STZ (Streptozocin) according to 45mg per 100mg of weight. The PCOS with type 2 diabetes mellitus model is successfully established for the first time; the construction time of the model is short and the success rate is high; a testing method is simple and feasible; the model is good in repeatability and low in cost and is an ideal PCOS with type 2 diabetes mellitus model.

The invention discloses a method for inhibiting dimethylbenzanthracene-induced rat mammary cancer with fucoidan, which relates to the technical field of mammary cancer inhibition. Sixty SPF (Specific Pathogen Free ) grade female SD (Sprague-Dawley) rats are randomly divided into a blank control group, a model control group, a low-dose fucoidan intervention group and a high-dose fucoidan intervention group according to body weights, fifteen rats in each group, the rats are killed after sixteen weeks, the incubation period and tumor inhibition rate of the mammary cancer of each group of rats are calculated, and thymus indexes, spleen indexes and the like are calculated. ELISA (enzyme-linked immunosorbent assay) is adopted to assay the levels of interleukins IL-6, IL-10 and IL-12, interferon-Gamma and transforming growth factor-Beta in serum, and a flow cytometer is utilized to assay the activity of NK (natural killer) cells in the peripheral blood of the rats and the cell percentage of the T-lymphocytes subset. The method has the following advantages that the method can regulate the immunity of rats, enhance antitumor immunity and relieve the immunosuppression of tumors, and the regulation of the activity of immune cells by fucoidan is one of the mechanisms of fucoidan in inhibiting the occurrence of mammary cancer.

The invention discloses a novel method for establishing a vascular dementia rat model. According to the novel method, a 6-week old male clean and healthy Sprague Dawley (SD) rat with the weight of 180-220g is subjected to long-term gavage by adopting isocarbophos, wherein the gavage concentration of the isocarbophos is 0.5mg/kg, the gavage capacity is 3ml/kg, the gavage frequency is one time every other day, and the gavage period is 24 weeks. The vascular dementia rat model is established through chronic damage of the isocarbophos to the brain vessels and brain nervous tissues of the SD rat.

The invention provides application of lovastatin to preparing Toll-like receptor 4 signaling pathway activation inhibitors and application of lovastatin to preparing microglial cell downstream inflammatory factor expression inhibitor and microglial cell inflammatory signaling pathway activation inhibitors. In vitro experiments prove that, in microglial cells processed and activated by endotoxins,the level of content of nitric oxide, hydrogen peroxide, reactive oxygen and inflammatory factors can be significantly increased; applied lovastatin can significantly inhibit release of nitric oxide,hydrogen peroxide and reactive oxygen and expression of the inflammatory factors; in BV-2 cells, the nitric oxide inhibiting activity of lovastatin is 11.6-13.8 mu M. In vivo experiments prove that lovastatin can reduce in vivo neuropathic pain of Sprague-Dawley rats and inhibit expression of a microglial cell activation marker of CD11b, thereby signifying the effects of lovastatin on specific regulation of microglial cell activation.

The invention discloses a method for separating and cultivating endothelial cells of common carotid arteries of SD (Sprague Dawley) rats. The method includes steps of 1), incising the common carotid arteries of the SD rats under sterile conditions; 2), cutting and segmenting the common carotid arteries, then stripping outer membranes from the common carotid arteries in PBS (poly butylenes succinate) liquor, longitudinally cutting the common carotid arteries, downwardly flatly spreading inner membranes in containers filled with digestive enzyme liquor and enabling the inner membranes of the common carotid arteries to be in sufficient contact with the digestive enzyme liquor in the containers; 3), vibrating the containers to allow the endothelial cells to fall off, removing the common carotid arteries after digestion is completed, adding fetal bovine serum into the containers and uniformly stirring the fetal bovine serum to obtain mixed liquid; 4), centrifuging the mixed liquid, removing supernatants to obtain the endothelial cells of the common carotid arteries, cultivating the endothelial cells of the common carotid arteries in endothelial cell cultivation media, transferring the endothelial cells to cultivation tanks to cultivate the endothelial cells after the endothelial cells reach log phases and then carrying out generation cultivation on the endothelial cells. The method has the advantages of high survival rate, little cell injury, economic efficiency, practicality, simplicity, feasibility and applicability to mass production in factories and the like.